As of Wednesday, April 29, Intellia Therapeutics, Inc.’s NTLA share price has dipped by 6.01%, which has investors questioning if this is right time to buy.
Barchart on MSN
Intellia Therapeutics stock is down nearly 95% from its record highs but Cathie Wood keeps buying
Intellia Therapeutics (NTLA) is a clinical-stage biotech firm working on CRISPR-based treatments that try to edit genes ...
In biotech, success often begins in the lab — and for CRISPR pioneers, every clinical trial feels like a moonshot. Gene-editing is not just science but rewriting life itself. For clinical-stage ...
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to a loss of $1.31 per share a year ago.
Intellia Therapeutics (NASDAQ:NTLA) jumped about 25%on Monday as investors positioned for data from its Phase 3 HAELO study of lonvoguran ziclumeran, a gene-editing treatment for hereditary angioedema ...
Whitney Ijem at Canaccord boosted his firm's price target from $48 to $58 last week, encouraged by recent positive data from ...
Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results